Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Settlement Encompasses Whistleblower Claims Of Kickbacks For Diovan Prescribing

This article was originally published in The Pink Sheet Daily

Executive Summary

The company agrees to pay $422.5 million to resolve civil and criminal claims related to off-label use and kickbacks, including allegations that it paid doctors' speaking and consulting fees based upon the volume of prescriptions they wrote for its hypertension drugs.

You may also be interested in...



Entresto Hurdles Dog Novartis

Entresto's slow market start following its US approval prompted many questions as Novartis AG reported its quarterly results Oct. 27.

Kickback Suit Against Novartis Can Proceed, Judge Says

Federal judge rules against Novartis’ motion to dismiss a whistleblower suit alleging violations of the anti-kickback statute and the False Claims Act, saying the government’s evidence is specific enough to proceed.

Health Care Fraud Tipsters May Get Bigger Reward; Novartis Kickback Complaint Prompts CIA Review

HHS proposes to increase the potential reward for information leading to recovery of Medicare funds from $1,000 to $9.9 million; OIG is reviewing Novartis corporate integrity agreement compliance after government alleges company paid Myfortic kickbacks to pharmacies.

Related Content

Topics

UsernamePublicRestriction

Register

PS071289

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel